In the Phase 2 CONNECT1-EDO51 Trial for DMD Amenable to Exon 51 Skipping, patient dosing has started.

Published Date: 29 Feb 2024

The first patient in PepGen's phase 2 CONNECT1-EDO51 trial has received a dose of PGN-EDO51, an agent for Duchenne muscular dystrophy that can be amended by skipping exon 51.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot